leisure time -WSS

leisure time

author：focus 2025-08-10 11:42:35 - browse：68849

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： EPA limits use of carcinogenic gas for sterilizing medical devices

entertainment

WSS

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Pushing for an NIH office for post

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

What is STAT's opinion section for?

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

knowledge

leisure time

Wikipedia

Drug repurposing or repositioning? The language matters

What health policies could hitch a ride on a spending bill?

Apple is now the first public company to be valued at $3 trillion

First U.S. drug developed to treat liver disease MASH is approved

At least 13 dead in Texas as scorching temps continue

What health policies could hitch a ride on a spending bill?

Dobbs anniversary: the lost opportunity of abortion as health care

How to save health care price transparency rules

Moonlake's readout produced a cash windfall. Risks remain

Cancer diagnosis changes perspective doctor, former hospital CEO

leisure time

John Green on his newest strategy for fighting tuberculosis

First transplant of an entire human eye performed

Why scientists need input from humanists on sensitive research

NIH chief: government has fallen behind pharma on clinical trials

Readout Newsletter: CAR

Pushing for an NIH office for post

leisure time

entertainment

focus

hotspot